Skip to main content

Table 2 Characteristics of eligible trials for general sarcoma with biologically based treatment for phase I and phase II

From: Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

Author

Year

Intervention

No Osteo Patients

No Ewing Patients

Phase

Outcome

Daw et al, J Clin Oncol, 23 (25): 6172-80 [40]

2005

Gefitinib

6

3

I

1 (4%) PR, 4 (16%) SD

Maki et al, Cancer, 103 (7): 1431-8 [41]

2005

Bortezomib

1

2

II

1 (4%) OR

Villablanca et al, J Clin Oncol, 24 (21): 3423-30 [42]

2006

Fenretinide

2

5

I

1 (2%) CR, 13 (24%) SD

Biron et al, ASCO abstract

2007

Gimatecan

0

Not mentioned

II

3 (8%) SD

Bagatell et al, Clin Cancer Res, 13 (6): 1783-8 [43]

2007

Tanespimycin

6

2

I

0% OR

Jimeno et al, Pediatr Blood Cancer, 49 (3): 352-7 [44]

2007

Gefitinib

3

1

I

1 (7%) PR, 3 (20%) SD

Kramer et al, J Clin Oncol, 25 (34): 5465-70 [45]

2007

Monoclonal antibody(131-I-3F8)

0

2

I

3 (23%) ClR

Bond et al, Pediatr Blood Cancer, 50 (2): 254-8 [46]

2008

Imatinib mesylate

10

24

II

1 (1%) PR

Chao et al, ASCO abstract

2008

Imatinib mesylate

0

7

II

1 (14%) PR

Fox et al, Clin Cancer Res, 14 (4): 1111-5 [47]

2008

Tubulin Inhibitor (ABT-751)

3

3

I

0% OR

Jakacki et al, J Clin Oncol, 26 (30): 4921-7 [48]

2008

Erlotinib, Temozolomide

1

0

I

1 (2%) SD

Langevin et al, Pediatr Blood Cancer, 50 (3): 577-80 [49]

2008

Rebeccamycin

16

14

II

% OR

Mita et al, J Clin Oncol, 26 (3): 361-7 [50]

2008

Deforolimus

1

1

I

4 (13%) PR, 18 (56%) SD

Olmos et al, ASCO abstract

2008

Figitumumab

0

9

I

1 (5%) PR, 6 (27%) SD

Chawla et al, Mol Ther, 17 (9): 1651-7 [51]

2009

Rexin-G

3

1

I/II

13 (65%) SD

Chugh et al, J Clin Oncol, 27 (19): 3148-53 [52]

2009

Imatinib

27

13

II

1 (0.5%) CR, 3 (2%) PR

Malempati et al, ASCO abstract

2009

Cixutumumab

Not mentioned

10

I

1 (4%) PR

Patel et al, ASCO abstract

2009

IGF-1R antibody (R1507)

43

71

II

Not mentioned

Widemann et al, J Clin Oncol, 27 (4): 550-6 [53]

2009

Ixabepilone

3

2

I

4 (21%) SD

Jacobs et al, Clin Cancer Res, 16 (2): 750-4 [54]

2010

Ixabepilone

11

9

II

0% OR

Kurzrock et al, Clin Cancer Res, 16 (8): 2458-65 [55]

2010

IGF-1R antibody (R1507)

0

9

I

2 (5%) PR, 13 (35%) SD

Olmos et al, Lancet Oncol, 11: 129-35 [56]

2010

Figitumumab

0

16

I

1 (3%) CR, 1 (3%) PR, 8 (28%) SD

  1. Abbreviations:, ClR = Clinical Response; CR = Complete Response; Cyclo = cyclophosphamide; Doxo = doxorubicin; EFS = Event Free Survival; Etop = etoposide; Ewing = Ewing Sarcoma; Ifos = ifosfamide; No = number; OR = Objective Response; Osteo = Osteosarcoma; PR = Partial Response; RR = Response Rate; SCR = Stem Cell Rescue; SD = Stabile Disease; TMR = Total Marrow Radiation; Vin = vincristine